Avacta Analytical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Avacta Analytical


Avacta Analytical, a leading provider of analytical services and technologies, has unveiled the Optim® 2 microvolume protein analysis and characterisation instrument. This compact and robust system combines the powerful protein characterisation capabilities of the original Optim 1000 instrument with a new, application-oriented software package designed to increase throughput and functionality. The Optim 2 features an enhanced sample positioning system to offer even greater measurement accuracy and reproducibility, and has been designed to simplify servicing and maintenance for maximum uptime.

The Optim 1000 was developed to reduce the time and cost of therapeutic protein formulation studies and protein stability testing by offering simultaneous measurement of a range of protein stability indicating parameters, including unfolding transition temperature (Tm) and aggregation onset temperature (Tagg). The Optim 2 builds on the success of this instrument, providing greater functionality and measurement flexibility in a more user-oriented, application-focused package. Its intuitive control software has been developed around common protein development workflows, offering quick and easy access to a range of pre-programmed measurement types for faster method development. Combined with a powerful and easy-to-use analytical package, this provides a comprehensive and cost-effective solution for stability screening of candidate molecules or formulations much earlier in the development process.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here